Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis

Med Lett Drugs Ther. 2018 Oct 22;60(1558):174-176.

Abstract

No abstract available

Keywords: Kalydeco; Orkambi; Symdeko; adverse effects; cystic fibrosis; dosage; drug interactions; efficacy; ivacaftor; lumacaftor; pregnancy; safety; tezacaftor.

MeSH terms

  • Administration, Oral
  • Aminophenols / administration & dosage*
  • Aminophenols / adverse effects
  • Aminophenols / pharmacokinetics
  • Aminopyridines / administration & dosage
  • Benzodioxoles / administration & dosage*
  • Benzodioxoles / adverse effects
  • Benzodioxoles / pharmacokinetics
  • Cystic Fibrosis / diagnosis
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis / metabolism
  • Cystic Fibrosis Transmembrane Conductance Regulator / agonists*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Drug Administration Schedule
  • Drug Combinations
  • Drug Interactions
  • Humans
  • Indoles / administration & dosage*
  • Indoles / adverse effects
  • Indoles / pharmacokinetics
  • Lung / drug effects*
  • Lung / metabolism
  • Membrane Transport Modulators / administration & dosage*
  • Membrane Transport Modulators / adverse effects
  • Membrane Transport Modulators / pharmacokinetics
  • Mutation
  • Quinolones / administration & dosage*
  • Quinolones / adverse effects
  • Quinolones / pharmacokinetics
  • Treatment Outcome

Substances

  • Aminophenols
  • Aminopyridines
  • Benzodioxoles
  • CFTR protein, human
  • Drug Combinations
  • Indoles
  • Membrane Transport Modulators
  • Quinolones
  • lumacaftor, ivacaftor drug combination
  • tezacaftor
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • ivacaftor